Piribo logo
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report offering an outlook of pharmaceutical market in Brazil.
“The Pharmaceutical Market: Brazil - Opportunities and Challenges”, available at http://tinyurl.com/
The pharmacy sector in dollar values performed exceptionally well in 2008, however the sector is has started to register slower growth in the first quarter of 2009. Generic medicines continue to grow at a higher rate than overall pharmacy sales and are expected to represent 20% of the sector by volume in 2010. Further, foreign participation in the generic sector has increased following the announcement of the Sanofi-aventis' acquisition of Medley.
According to the 194-page report, the Chamber for the Regulation of Medicines (CMED) has authorised price increases on nearly 18,000 drug presentations which are controlled. Annual price adjustments are based on price ceilings which are calculated taking into account the National Broad Consumer Index (IPCA) between March 2008 and February 2009, a productivity factor, equal to 0.0% in 2009, and inter- and intra-sector factors.
Brazil has a history of talking tough with foreign producers. Under Decree 4,830/2003, Brazil allowed compulsory licensing in cases of national emergency or public interest. Brazil issued its first compulsory licence in May 2007, for Merck Sharp & Dohme's Stocrin (efavirenz). Rising patient numbers, increasing resistance levels, rising costs and high-risk behaviour are factors which will continue to threaten HIV/AIDS patents.
The report “The Pharmaceutical Market: Brazil - Opportunities and Challenges” is available from Piribo. For further information, please visit:
http://www.piribo.com/
Piribo product ID: ESP00333
Photo:
http://www.prlog.org/
